Due to its highly restricted pattern of expression, PRAME has emerged as an attractive target for cancer immunotherapy, in which cytotoxic T lymphocytes are developed to selectively target and eliminate PRAME-positive cancer cells [21,35,36,37,38]. Here, PRAME is linked to cancer.